Stay updated with breaking news from Biliary Tract. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Antibiotic use doesn’t appear to disrupt the effectiveness of the immune checkpoint inhibitor durvalumab in advanced biliary tract cancer, according to a new analysis of TOPAZ-1 clinical trial data.
Investegate announcements from AstraZeneca PLC, Imfinzi recommended for approval in the EU for BTC
AstraZeneca's Imfinzi recommended for approval in EU for BTC
AstraZeneca’s Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The Committee for Medicinal Products ...
HIMALAYA Phase III trial exploratory results support the benefit of tremelimumab added to IMFINZI in unresectable liver cancer regardless of etiology Updated results from the TOPAZ-1 Phase III trial